Praveen S.

Praveen S. is an experienced clinical pharmacology professional currently serving as Associate Director of Translational Medicine at Vertex Pharmaceuticals since May 2020, providing leadership for the first CRISPR/Cas9 gene-edited therapy, CASGEVY®, aimed at treating sickle cell disease and transfusion-dependent beta-thalassemia. Prior to this role, Praveen S. held positions as Senior Clinical Pharmacology Scientist and Clinical Pharmacology Scientist II at the University of California, San Francisco, where projects focused on optimizing conditioning regimens for bone marrow transplant patients. Praveen S. also contributed as a Research Scientist at Stanford University School of Medicine and completed a postdoctoral fellowship in Cardiac and Cellular Electrophysiology. Academic credentials include a Doctor of Pharmacy from the University of California, San Francisco, a postdoctoral fellowship from Stanford University, a Master of Science in Pharmacology and Toxicology from NIPER Mohali, a Bachelor of Pharmacy from Nagpur University, and a Diploma in Pharmacy from AICTE.